Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK

被引：25

作者：

Shields, Adrian M. ^{[1
]}

Anantharachagan, Ariharan ^{[2
]}

Arumugakani, Gururaj ^{[3
]}

Baker, Kenneth ^{[4
,5
]}

Bahal, Sameer ^{[6
]}

Baxendale, Helen ^{[7
]}

Bermingham, William ^{[8
]}

Bhole, Malini ^{[9
]}

Boules, Evon ^{[10
]}

Bright, Philip ^{[11
]}

Chopra, Charu ^{[12
]}

Cliffe, Lucy ^{[13
]}

Cleave, Betsy ^{[13
]}

Dempster, John ^{[14
]}

Devlin, Lisa ^{[15
]}

Dhalla, Fatima ^{[16
]}

Diwakar, Lavanya ^{[17
]}

Drewe, Elizabeth ^{[13
]}

Duncan, Christopher ^{[18
]}

Dziadzio, Magdalena ^{[19
]}

Elcombe, Suzanne ^{[20
]}

Elkhalifa, Shuayb ^{[21
]}

Gennery, Andrew ^{[22
,23
]}

Ghanta, Harichandrana ^{[24
]}

Goddard, Sarah ^{[17
]}

Grigoriadou, Sofia ^{[25
]}

Hackett, Scott ^{[26
]}

Hayman, Grant ^{[27
]}

Herriot, Richard ^{[28
]}

Herwadkar, Archana ^{[21
]}

Huissoon, Aarnoud ^{[8
]}

Jain, Rashmi ^{[16
]}

Jolles, Stephen ^{[29
]}

Johnston, Sarah ^{[11
]}

Khan, Sujoy ^{[30
]}

Laffan, James ^{[27
]}

Lane, Peter ^{[1
]}

Leeman, Lucy ^{[31
]}

Lowe, David M. ^{[6
,32
]}

Mahabir, Shanti ^{[33
]}

Mac Lochlainn, Dylan James ^{[16
]}

McDermott, Elizabeth ^{[13
]}

Misbah, Siraj ^{[16
]}

Moghaddas, Fiona ^{[11
]}

Morsi, Hadeil ^{[16
]}

Murng, Sai ^{[27
]}

Noorani, Sadia ^{[34
]}

O'Brien, Rachael ^{[35
]}

Patel, Smita ^{[16
]}

Price, Arthur ^{[33
]}

机构：

[1] Univ Birmingham, Inst Immunol & Immunotherapy, Clin Immunol Serv, Birmingham, W Midlands, England

[2] Lancashire Teaching Hosp NHS Fdn Trust, Preston, Lancs, England

[3] Leeds Teaching Hosp NHS Trust, Dept Clin Immunol & Allergy, St James Univ Hosp, Leeds, W Yorkshire, England

[4] Newcastle Univ, NIHR Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England

[5] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England

[6] Royal Free London NHS Fdn Trust, Dept Immunol, London, England

[7] Royal Papworth NHS Fdn Trust, Cambridge, England

[8] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England

[9] Dudley Grp NHS Fdn Trust, Birmingham, W Midlands, England

[10] Sheffield Teaching Hosp NHS Fdn Trust, Clin Immunol & Allergy Dept, Sheffield, S Yorkshire, England

[11] North Bristol NHS Trust, Clin Immunol, Bristol, Avon, England

[12] Royal Infirm Edinburgh NHS Trust, Dept Haematol & Immunol, NHS Lothian, Edinburgh, Midlothian, Scotland

[13] Nottingham Univ Hosp NHS Trust, Clin Immunol & Allergy Dept, Nottingham, England

[14] Univ Coll London Hosp, Specialist Allergy & Clin Immunol, London, England

[15] Royal Hosp, Reg Immunol Serv, Belfast, Antrim, North Ireland

[16] Oxford Univ Hosp NHS Fdn Trust, Dept Clin Immunol, Oxford, England

[17] Royal Stoke Hosp, Dept Immunol, Stoke On Trent, Staffs, England

[18] Newcastle Univ, Translat & Clin Res Inst, Immun & Inflammat Theme, Newcastle Upon Tyne, Tyne & Wear, England

[19] UCL, Ear Inst, London, England

[20] Newcastle Upon Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Reg Dept Clin Immunol & Allergy, Newcastle Upon Tyne, Tyne & Wear, England

[21] Salford Royal NHS Fdn Trust, Immunol Dept, Manchester, Lancs, England

[22] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England

[23] Great North Children S Hosp, Paediat Stem Cell Transplant Unit, Newcastle Upon Tyne, Tyne & Wear, England

[24] Univ Southampton, Univ Hosp Southampton NHS Trust, Dept Allergy & Clin Immunol, Southampton, Hants, England

[25] Barts Hlth NHS Trust, Immunol Dept, Royal London Hosp, London, England

[26] Univ Hosp Birmingham, Paediat Immunol Dept, Birmingham, W Midlands, England

[27] Epsom & St Helier Univ Hosp NHS Trust, Clin Immunol Serv, South West London Immunodeficiency Ctr, London, England

[28] Aberdeen Royal Infirm, Immunol Dept, Aberdeen, Scotland

[29] Univ Hosp Wales, Immunodeficiency Ctr Wales, Heath Pk, Cardiff, Wales

[30] Hull Univ Teaching Hosp NHS Trust, Kingston Upon Hull, N Humberside, England

[31] Univ Hosp Plymouth NHS Trust, Plymouth, Devon, England

[32] UCL, Inst Immun & Transplantat, London, England

[33] Leicester Royal Infirm, Clin Immunol & Allergy Dept, Leicester, Leics, England

[34] Sandwell & West Birmingham Hosp NHS Trust, Clin Immunol Dept, Birmingham, W Midlands, England

[35] Frimley Pk Hosp, Dept Clin Immunol, Frimley, Surrey, England

[36] NHS Greater Glasgow & Clyde, Clin Immunol Serv, Glasgow, Lanark, Scotland

来源：

CLINICAL AND EXPERIMENTAL IMMUNOLOGY | 2022年 / 209卷 / 03期

关键词：

COVID-19; SARS-CoV-2; hypogammaglobulinemia; inborn errors of immunity; primary immunodeficiencies; secondary immunodeficiencies; lymphopenia; COVID-19; IMMUNITY;

D O I：

10.1093/cei/uxac008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In March 2020, the United Kingdom Primary Immunodeficiency Network (UKPIN) established a registry of cases to collate the outcomes of individuals with PID and SID following SARS-CoV-2 infection and treatment. A total of 310 cases of SARS-CoV-2 infection in individuals with PID or SID have now been reported in the UK. The overall mortality within the cohort was 17.7% (n = 55/310). Individuals with CVID demonstrated an infection fatality rate (IFR) of 18.3% (n = 17/93), individuals with PID receiving IgRT had an IFR of 16.3% (n = 26/159) and individuals with SID, an IFR of 27.2% (n = 25/92). Individuals with PID and SID had higher inpatient mortality and died at a younger age than the general population. Increasing age, low pre-SARS-CoV-2 infection lymphocyte count and the presence of common co-morbidities increased the risk of mortality in PID. Access to specific COVID-19 treatments in this cohort was limited: only 22.9% (n = 33/144) of patients admitted to the hospital received dexamethasone, remdesivir, an anti-SARS-CoV-2 antibody-based therapeutic (e.g. REGN-COV2 or convalescent plasma) or tocilizumab as a monotherapy or in combination. Dexamethasone, remdesivir, and anti-SARS-CoV-2 antibody-based therapeutics appeared efficacious in PID and SID. Compared to the general population, individuals with PID or SID are at high risk of mortality following SARS-CoV-2 infection. Increasing age, low baseline lymphocyte count, and the presence of co-morbidities are additional risk factors for poor outcome in this cohort. Individuals with immunodeficiency are at increased risk of severe infection. This study looks at outcomes following SARS-CoV-2 infection in 310 patients with primary or secondary immunodeficiency in the United Kingdom and finds significantly elevated mortality in both cohorts compared to the general population. Increasing age, pre-existing lymphopenia and other co-morbidities are identified as additional risk factors for death from COVID-19 in this cohort.

引用

页码：247 / 258

页数：12

共 28 条

[21] Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials
Moran, Ed
Cook, Tim
Goodman, Anna L.
Gupta, Ravindra K.
Jolles, Stephen
Menon, David K.
Roberts, David J.
Savic, Sinisa
Shankar-Hari, Manu
Brown, Michael
Lowe, David M.
[J]. LANCET INFECTIOUS DISEASES, 2021, 21 (10) : 1345 - 1347
[22] COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience
Shields, Adrian M.
Burns, Siobhan O.
Savic, Sinisa
Richter, Alex G.
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (03) : 870 - +
[23] UK Government, GUID PROT PEOPL WHO
[24] UK Government, COR COVID 19 UK
[25] Immunology of COVID-19: Current State of the Science
Vabret, Nicolas
Britton, Graham J.
Gruber, Conor
Hegde, Samarth
Kim, Joel
Kuksin, Maria
Levantovsky, Rachel
Malle, Louise
Moreira, Alvaro
Park, Matthew D.
Pia, Luisanna
Risson, Emma
Saffern, Miriam
Salome, Berengere
Selvan, Myvizhi Esai
Spindler, Matthew P.
Tan, Jessica
van der Heide, Verena
Gregory, Jill K.
Alexandropoulos, Konstantina
Bhardwaj, Nina
Brown, Brian D.
Greenbaum, Benjamin
Gumus, Zeynep H.
Homann, Dirk
Horowitz, Amir
Kamphorst, Alice O.
de Lafaille, Maria A. Curotto
Mehandru, Saurabh
Merad, Miriam
Samstein, Robert M.
[J]. IMMUNITY, 2020, 52 (06) : 910 - 941
[26] Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study
Warny, Marie
Helby, Jens
Nordestgaard, Borge Gronne
Birgens, Henrik
Bojesen, Stig Egil
[J]. PLOS MEDICINE, 2018, 15 (11)
[27] REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M.
Sivapalasingam, S.
Norton, T.
Ali, S.
Gao, H.
Bhore, R.
Musser, B. J.
Soo, Y.
Rofail, D.
Im, J.
Perry, C.
Pan, C.
Hosain, R.
Mahmood, A.
Davis, J. D.
Turner, K. C.
Hooper, A. T.
Hamilton, J. D.
Baum, A.
Kyratsous, C. A.
Kim, Y.
Cook, A.
Kampman, W.
Kohli, A.
Sachdeva, Y.
Graber, X.
Kowal, B.
DiCioccio, T.
Stahl, N.
Lipsich, L.
Braunstein, N.
Herman, G.
Yancopoulos, G. D.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (03) : 238 - 251
[28] Factors associated with COVID-19-related death using OpenSAFELY
Williamson, Elizabeth J.
Walker, Alex J.
Bhaskaran, Krishnan
Bacon, Seb
Bates, Chris
Morton, Caroline E.
Curtis, Helen J.
Mehrkar, Amir
Evans, David
Inglesby, Peter
Cockburn, Jonathan
McDonald, Helen, I
MacKenna, Brian
Tomlinson, Laurie
Douglas, Ian J.
Rentsch, Christopher T.
Mathur, Rohini
Wong, Angel Y. S.
Grieve, Richard
Harrison, David
Forbes, Harriet
Schultze, Anna
Croker, Richard
Parry, John
Hester, Frank
Harper, Sam
Perera, Rafael
Evans, Stephen J. W.
Smeeth, Liam
Ben Goldacre
[J]. NATURE, 2020, 584 (7821) : 430 - +

← 1 2 3 →